|
KMID : 0882420220970040229
|
|
Korean Journal of Medicine
2022 Volume.97 No. 4 p.229 ~ p.237
|
|
|
Chimeric Antigen Receptor-T Cell Therapy
|
|
Byun Ja-Min
Yoon Sung-Soo
|
|
|
Abstract
|
|
|
Chimeric antigen receptor (CAR) T-cell therapy constitutes a revolutionary advancement in personalized cancer treatment.
During this treatment, a patient's own T cells are genetically engineered to express a synthetic receptor that binds a tumor antigen.
CAR-T cells are then expanded for clinical use and infused back into the patient's body to attack cancer. CAR-T cells have produced remarkable clinical responses with B-cell malignancies. However, CAR-T cells therapy is not without problems. Barriers to effective CAR-T cells therapy include severe life-threatening toxicities and modest anti-tumor activity. In this review, we introduce the concept of CAR-T cells therapy, currently available CAR-T cells therapy options, and how to deal with adverse events.
|
|
|
KEYWORD
|
|
|
Chimeric antigen receptor, CAR-T cell therapy, Lymphoma, Multiple myeloma
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
  
|